AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30528849
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation (carbohydrates, proteins, electrolytes, osmolarity of 680 mO.L‐1, 300 kcal)
Trial: 30528849
Drug: Isotonic solution
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic solution (carbohydrates, electrolytes, osmolarity of 292 mOsm.L‐1, 36 kcal)
Trial: 30528849
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between isotonic solution and nutritional supplementation
Trial: 24507377
Drug: EMA401 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMA401 (100 mg twice daily)
Trial: 19443189
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with purified air
Trial: 19443189
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with unfiltered air
Trial: 17192489
Drug: Rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (8 mg/day) and Fenofibrate (160 mg/day)
Trial: 9555866
Drug: Fat-rich breakfast
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-rich breakfast with palmitic acid (21.7 g)
Trial: 9555866
Drug: Fat-rich breakfast
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-rich breakfast with stearic acid (18.6 g)
Trial: 3419245
Drug: Atropine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (2 mg)
Trial: 3933861
Drug: Pirenzepine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (20 mg)
Trial: 3419245
Drug: Atropine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (1 mg and 2 mg)
Trial: 25273077
Drug: S-1 in
RxNorm normalized name: PTGS-1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 in combination with leucovorin (SL)
Trial: 20228415
Drug: 5-lipoxygenase inhibitor
RxNorm normalized name: 5-lipoxygenase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-lipoxygenase inhibitor
Trial: 8841865
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with epinephrine (5 micrograms/mL)
Trial: 26062189
Drug: Flurphen mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurphen mixture (droperidol injection 1.25 mg and fentanyl citrate injection 0.05 mg diluted to 6 mL with 0.9% sodium chloride solution 4.5 mL) injected at bilateral Shenshu (BL 23) 15 to 20 min before ESWL.
Trial: 26062189
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no adjuvant therapy or medication before ESWL.
Trial: 22151934
Drug: L‐ascorbic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐ascorbic acid 10% + phytic acid 2%
Trial: 1955161
Drug: Adrenaline injection
RxNorm normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenaline injection (1:10,000)
Trial: 17561127
Drug: Intraprostatic local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraprostatic local anesthesia with 2 ml 1% lidocaine and periprostatic injection of 2 ml saline (Group 1)
Trial: 17561127
Drug: Intraprostatic injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraprostatic injection of 2 ml saline followed by periprostatic local anesthesia with 2 ml 1% lidocaine (Group 2)
Trial: 17561127
Drug: Intraprostatic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraprostatic and periprostatic local anesthesia with 2 ml 1% lidocaine (Group 3)
Trial: 27506971
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline injection)
Trial: 11158797
Drug: Fixed-combination latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-combination latanoprost 0.005%-timolol 0.5% (FC, n = 116)
Trial: 1973905
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral dose of gepirone
Trial: 1973905
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg gepirone (acute administration)
Trial: 1973905
Drug: Chronic administration
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic administration of gepirone (3-6 weeks)
Trial: 13090
Drug: Anisotropine methylbromide
RxNorm normalized name: Anisotropine methylbromide
DrugBank: Anisotropine methylbromide (DB00517)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anisotropine methylbromide (high doses)
Trial: 21846343
Drug: Omega-3 polyunsaturated
RxNorm normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 polyunsaturated fatty acids supplement
Trial: 21846343
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not given omega-3 supplements)
Trial: 17437662
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of different biochemical markers
Trial: 15156527
Drug: Dual ACE
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual ACE inhibitor-ARB therapy
Trial: 15156527
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors and ARBs (combined)
Trial: 15156527
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (from trials)
Trial: 2689236
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with short-term (ST) 5-FU (575 mg/m2 daily for 4 days before irradiation)
Trial: 2689236
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with long-term (LT) 5-FU (750 mg/m2 every 2 weeks for 18 months)
Trial: 25805811
Drug: Low-dose Ara-C
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Ara-C (LDAC)
Trial: 30974973
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec (degludec) using FlexTouch1
Trial: 16512939
Drug: Algal oil
RxNorm normalized name: Algal Oil
DrugBank: Schizochytrium DHA oil (DB11069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algal oil containing 1.5 g DHA and 0.6 g DPA, 4 g oil/d for 4 weeks
Trial: 15165387
Drug: Conventional initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional initial treatment (RICE, rest, ice, compression, elevation)
Trial: 11167172
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (100 microg kg(‐1) min(‐1))
Trial: 9263157
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 30 mg ketoprofen plaster once daily for 5 days (n = 30)
Trial: 9263157
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 50 mg ketoprofen (n = 30)
Trial: 8390329
Drug: lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine 2% with adrenaline 1:200,000 plus 0.1 mEq.ml‐1 sodium bicarbonate
Trial: 26561996
Drug: Plasma of
RxNorm normalized name: HUMAN IGG POLYCLONAL ANTIBODY DERIVED FROM PLASMA OF TRANSCHROMOSOMAL BOVINE TARGETED TO THE SPIKE PROTEIN OF SARS COV-2
DrugBank: SAB-185 (DB16491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma of argon treatment
Trial: 24040851
Drug: Nalfurafine 5
RxNorm normalized name: nalfurafine
DrugBank: Nalfurafine (DB13471)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Nalfurafine 5 μg intravenously after each hemodialysis session
Trial: 21385240
Drug: Clinical medication
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical medication review by community pharmacists
Trial: 16136309
Drug: monoHER (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monoHER (100 mg/m2 to 1,500 mg/m2, administered as an i.v. infusion in 10 min)
Trial: 16136309
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 ml dextrose 5%)
Trial: 12933531
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) with micronized progesterone (MP, 100 mg) and conjugated equine estrogen (CEE, 0.625 mg)
Trial: 11086281
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg tablets) taken daily for three months, during or outside meals
Trial: 11086281
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg tablets)
Trial: 9542771
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (25 grams of creatine monohydrate daily for three days)
Trial: 8268595
Drug: FUT-175 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUT-175 (2 mg/kg/hr)
Trial: 8268595
Drug: Control (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (sodium heparin 3 mg/kg)
Trial: 27020109
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment plans
Trial: 27020109
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plans
Trial: 24935755
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management (CM) with smoking abstinence-contingent incentives (expired CO < 6 ppm; urinary cotinine < 30 ng/ml) for 4 weeks
Trial: 26121348
Drug: Esomeprazole 5
RxNorm normalized name: esomeprazole 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 5 or 10 mg once daily
Trial: 12451199
Drug: CPI-1189 100
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPI-1189 100 mg/day
Trial: 12451199
Drug: CPI-1189 50
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPI-1189 50 mg/day
Trial: 10359461
Drug: Individual drug
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual drug counseling plus group drug counseling (GDC)
Trial: 10359461
Drug: Individual drug
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual drug counseling plus GDC
Trial: 10359461
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus GDC
Trial: 10359461
Drug: Supportive‐expressive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive‐expressive therapy plus GDC
Trial: 1664346
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 x 4 mg daily)
Trial: 7138720
Drug: i.m. morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. morphine
Trial: 28468518
Drug: sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual buprenorphine
Trial: 7066139
Drug: self-administered i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self-administered i.v. pethidine
Trial: 30407996
Drug: Intravenous Ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Ketorolac (IVK)
Trial: 23159967
Drug: Migraine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migraine treatment and H. pylori eradication treatment
Trial: 23159967
Drug: Migraine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migraine treatment and placebo (control)
Trial: 15902596
Drug: Suppliers medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suppliers medication leaflet
Trial: 7720296
Drug: Intracoronary adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary adenosine (100 mcg)
Trial: 2119419
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pravastatin once daily
Trial: 2119419
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pravastatin and resins
Trial: 7435893
Drug: Methylprednisolone 30
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 30 mg/kg in a single dose prior to bypass
Trial: 23473342
Drug: meloxicam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meloxicam (1 mg/kg PO)
Trial: 23473342
Drug: gabapentin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gabapentin (15 mg/kg PO)
Trial: 23473342
Drug: meloxicam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meloxicam (1 mg/kg) and gabapentin (15 mg/kg) PO
Trial: 23473342
Drug: flunixin (2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flunixin (2.2 mg/kg IV)
Trial: 22331114
Drug: Ganciclovir 0.15%
RxNorm normalized name: GANCICLOVIR 0.15% GEL,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir 0.15% ophthalmic gel
Trial: 19487950
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g i.v. paracetamol 20 min before and 4, 10 and 16 h after the end of the operation.
Trial: 19487950
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g i.v. metamizol scheduled at the same time points as paracetamol.
Trial: 19487950
Drug: Placebo scheduled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo scheduled at the same time points as paracetamol.
Trial: 19487950
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g i.v. paracetamol
Trial: 19487950
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g i.v. metamizol
Trial: 17160693
Drug: Duloxetine 20
RxNorm normalized name: duloxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 20 mg BID for 2 weeks escalating to 40 mg BID for 6 weeks
Trial: 17160693
Drug: Duloxetine 40
RxNorm normalized name: duloxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 40 mg BID for 8 weeks
Trial: 17160693
Drug: Duloxetine 40
RxNorm normalized name: duloxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 40 mg QD for 2 weeks escalating to 40 mg BID for 6 weeks
Trial: 11145489
Drug: Eptifibatide (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (two 180 microg/kg boluses 10 min apart and a continuous infusion of 2.0 microg/kg/min for 18‐24 h)
Trial: 2988393
Drug: Intramuscular supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular supplement of 30 mg of Vitamin D3 in monthly injections of 5 or 10 mg (Group II)
Trial: 29462997
Drug: Fibroin protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibroin protein enzymatic hydrolysate (FPEH) at doses of 280 mg, 400 mg, and 600 mg per day for 3 weeks
Trial: 29462997
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg FPEH)
Trial: 25826729
Drug: 12-week intervention
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week intervention consisting of a very-low-energy diet for the initial 6 weeks followed by a hypocaloric diet, combined with a weekly group multidisciplinary programme (n=27)
Trial: 19825849
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg IM methylprednisolone acetate
Trial: 16428154
Drug: Oral terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine 250 mg/day for 16 weeks
Trial: 16428154
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral terbinafine 250 mg/day for 16 weeks and topical ciclopirox nail lacquer once daily for 9 months
Trial: 8892765
Drug: Exercise rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise rehabilitation program + calcium heparin 12,500 IU subcutaneously 20 to 30 minutes before each exercise session
Trial: 1845132
Drug: rhEPO (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO (10,000 U five times weekly or 150-450 U/kg)
Trial: 1845132
Drug: rhGM-CSF (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM-CSF (250 g/m2/day x 14, s.c.) combined with Ara-C (20 mg/m2/day x 14, s.c.)
Trial: 30081019
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg body weight, administered intravenously at weeks 0, 4, 8, and 12)
Trial: 24385141
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with antioxidant vitamins and minerals
Trial: 22196768
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of PF-03654746 plus 60 mg of fexofenadine (group 1)
Trial: 22196768
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of PF-03654746 plus 60 mg of fexofenadine (group 2)
Trial: 22196768
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of fexofenadine/120 mg of pseudoephedrine (group 3)
Trial: 15776773
Drug: Topical clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clindamycin 1% benzoyl peroxide 5% gel (Duac)
Trial: 15776773
Drug: Topical clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clindamycin 1% benzoyl peroxide 5% gel (Duac) in combination with oral doxycycline hyclate (Doryx) and adapalene gel (Differin)
Trial: 12005454
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acid-based lipid emulsion (fish oil, 10%; 200 mL/d)
Trial: 12005454
Drug: n-6 lipid
RxNorm normalized name: 18:3 (n-6)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-6 lipid emulsion (soybean oil, 10%; 200 mL/d)
Trial: 10350383
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg od
Trial: 10350383
Drug: Levofloxacin 250
RxNorm normalized name: levofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 250 mg od
Trial: 10350383
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 250 mg bd
Trial: 2332608
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of prazepam in liquid drops
Trial: 2332608
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of prazepam in tablets
Trial: 7266731
Drug: Choline chloride
RxNorm normalized name: Choline Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline chloride (2 g QID)
Trial: 31928963
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sitagliptin daily for 3 consecutive cycles
Trial: 31928963
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo capsules
Trial: 15365580
Drug: Fluoxetine or
RxNorm normalized name: fluoxetine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine or desipramine (active treatment) for 8 weeks
Trial: 10874061
Drug: Antiarrhythmic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic therapy guided by electrophysiologic testing
Trial: 1552468
Drug: Minocycline periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline periodontal formulation
Trial: 1552468
Drug: Placebo periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo periodontal formulation
Trial: 3874932
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate with citrovorum factor rescue (MTX-CF)
Trial: 26483177
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of omalizumab
Trial: 26483177
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of omalizumab